PIQUR Therapeutics AG

PIQUR Therapeutics AG logo
🇨🇭Switzerland
Ownership
Holding
Established
2011-08-01
Employees
11
Market Cap
-
Website
http://www.piqur.com
Clinical Trials
Related News

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

Phase 2
Completed
Conditions
Lymphoma
Non-Hodgkin Lymphoma
Interventions
Drug: PQR309
First Posted Date
2017-04-25
Last Posted Date
2019-06-28
Lead Sponsor
PIQUR Therapeutics AG
Target Recruit Count
9
Registration Number
NCT03127020
Locations
🇩🇪

Medizinische Klinik und Poliklinik III, Munich, Bavaria, Germany

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Phase 2
Withdrawn
Conditions
Primary Central Nervous System Lymphoma
Interventions
Drug: PQR309
First Posted Date
2017-04-19
Last Posted Date
2018-11-16
Lead Sponsor
PIQUR Therapeutics AG
Registration Number
NCT03120000
Locations
🇫🇷

Hématologie, Départment d'ongolgie médicale, Saint-Herblain, France

🇫🇷

Aix-Marseilles Université, Marseille, France

🇫🇷

Service de Neurology CHRU de Nancy, Nancy, France

and more 1 locations

Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients

Phase 2
Terminated
Conditions
Glioblastoma Multiforme
Interventions
Drug: PQR309
First Posted Date
2016-08-01
Last Posted Date
2018-10-19
Lead Sponsor
PIQUR Therapeutics AG
Target Recruit Count
10
Registration Number
NCT02850744
Locations
🇨🇭

University Hospital Zurich, Neurology, Zurich, Switzerland

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Phase 1
Completed
Conditions
Metastatic Breast Cancer
Interventions
Drug: PQR309
Drug: Eribulin
First Posted Date
2016-03-31
Last Posted Date
2019-03-22
Lead Sponsor
PIQUR Therapeutics AG
Target Recruit Count
41
Registration Number
NCT02723877
Locations
🇬🇧

Churchill hospital, Oxford, United Kingdom

🇪🇸

Insitut Català d´Oncologia, Barcelona, Spain

🇬🇧

Barts Cancer Institute, London, United Kingdom

and more 2 locations

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Phase 2
Completed
Conditions
Primary Central Nervous System Lymphoma
Interventions
Drug: PQR309
First Posted Date
2016-02-01
Last Posted Date
2019-07-09
Lead Sponsor
PIQUR Therapeutics AG
Target Recruit Count
21
Registration Number
NCT02669511

Study of Oral PQR309 in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: PQR 309
First Posted Date
2015-06-29
Last Posted Date
2019-03-22
Lead Sponsor
PIQUR Therapeutics AG
Target Recruit Count
70
Registration Number
NCT02483858
Locations
🇺🇸

M.D. Anderson Cancer Center, Houston, Texas, United States

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Phase 2
Completed
Conditions
Lymphoma, Malignant
Interventions
Drug: bimiralisib
First Posted Date
2014-09-25
Last Posted Date
2019-09-06
Lead Sponsor
PIQUR Therapeutics AG
Target Recruit Count
53
Registration Number
NCT02249429
Locations
🇧🇦

University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina

🇬🇧

Royal Marsden NHS Foundation Trust, London, United Kingdom

🇬🇧

University College Hospital London, London, United Kingdom

and more 9 locations

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: PQR309
First Posted Date
2013-09-12
Last Posted Date
2017-04-12
Lead Sponsor
PIQUR Therapeutics AG
Target Recruit Count
28
Registration Number
NCT01940133
Locations
🇨🇭

University Hospital Basel, Basel, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy